Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 31, 2006
Grant Date -
Oct 24, 2002
app pub date -
Nov 29, 2001
filing date -
Dec 29, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully